Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Minnesota step therapy Co…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - MinnesotaPolicy N/A

    Step Therapy Requirements for Provider-Administered Specialty Medications

    Customize your policy alerts

    Sign up for all blue cross blue shield - minnesota policy alerts

    Know when blue cross blue shield - minnesota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy requirements for provider-administered specialty drugs listed in the document; applies to providers requesting coverage for these infused or injected specialty medications under Blue Cross Blue Shield - Minnesota.

    Policy Summary
    PayerBlue Cross Blue Shield - Minnesota
    PolicyStep Therapy Requirements for Provider-Administered Specialty Medications
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionRequesters must include the specific HCPCS/CPT/J/Q code(s) and document trial of one of the listed preferred alternative agents per the table when submitting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J & Qprocedure and drug billing codes referenced
    provider-administeredprovider-administered drugs required
    medically acceptedcoverage limited to
    20+distinct codes referenced
    1–5step positions referenced

    Coverage Criteria

    General coverage conditions

    Covered when ALL of the following are met

    Primary coverage conditions: The medication is a provider‑administered specialty drug; the drug is being used to treat a medically accepted indication; and the dose, frequency, and duration do not exceed safety and efficacy data supporting the medically accepted indication.

    These conditions are required for coverage per the policy preface.

    Product-specific step therapy

    Step therapy requirements per product (table-based)

    Product-specific step requirement: For each requested product listed in the table, the requester must trial one of the listed preferred alternative agents (column 2) prior to coverage of the requested product unless otherwise noted; each table row pairs requested products with specific HCPCS/CPT/Q codes and preferred alternatives.

    See the table rows for exact agent-to-code mappings and any product-specific notes (e.g., 'unless otherwise noted').

    Policy Summary
    PayerBlue Cross Blue Shield - Minnesota
    PolicyStep Therapy Requirements for Provider-Administered Specialty Medications
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionRequesters must include the specific HCPCS/CPT/J/Q code(s) and document trial of one of the listed preferred alternative agents per the table when submitting prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaStep Therapy Tables and MappingsHCPCS / CPT / Q-Code MappingsProvider Actions, Prior Authorization & DocumentationBackgroundDefinitionsInitial Therapy CriteriaSite of CareBiosimilar Notes and Mappings

    Step-based coverage sequencing

    Coverage follows the enumerated step levels for each drug/product as listed

    Step levels: Each product listing includes numbered step positions (1, 2, 3, 4, etc.) with associated codes; prior authorization and coverage decisions adhere to the listed step sequencing for the product group.

    Document fragment maps products to numbered steps; clinical failure definitions are not present in these excerpts.

    Step position mapping (code-driven)

    Coverage is determined by mapped HCPCS/J-code and step position as listed; the document assigns products to step positions 1–4.

    Step mapping requirement: The HCPCS/J (or Q) code submitted for the administered product must match the policy's mapped step position for that product; products designated as step 1 must be used/attempted before products mapped to later steps per the table.

    Providers must request prior authorization using the HCPCS/J/Q code that corresponds to the mapped step position.

    Step therapy groupings (initial agent then alternative options)

    Coverage follows step therapy sequences where a specified initial agent (by name and code) must be considered and then one of listed alternative agents may be used.

    Step grouping example: An initial agent or code is listed (e.g., Avastin, Lucentis, Soliris, Uplizna) at a numbered step; each initial entry is followed by 'Then one of the following:' and an enumerated list of allowed alternative agents/codes that satisfy the step requirement.

    Multiple groupings appear across the policy where an initial agent is specified and then alternatives are enumerated for subsequent steps.

    Step Therapy sequencing

    Coverage follows an ordered step-therapy approach: an initial agent followed by specified alternatives at subsequent steps.

    Step sequence requirement: The requested agent must correspond to the established step position for that drug group; initial agents (often Avastin or another listed first‑step drug) are followed by 'Then one of the following' lists of permitted alternatives for later steps, and providers must document prior-step use as required.

    Steps are enumerated (commonly 1–5) and coverage for later-step agents is contingent on compliance with the sequence.

    Step therapy group sequencing

    Coverage follows specified step/group sequences:

    grouped_steps: The policy enumerates multiple numbered step groups (1–5) for various product families (e.g., ophthalmic anti‑VEGF agents, rituximab products, viscosupplements) where coverage of a target product is contingent upon trial of one of the alternatives listed in the corresponding numbered step.

    Exact clinical indications, failure criteria, and exception rules are distributed across the full policy; these chunks enumerate product and code options per step.

    Some listed biosimilars and branded agents are limited to oncology or non‑cosmetic indications as shown in the step tables. For example, several bevacizumab entries include the annotation “For oncology indications only” (Bevacizumab/Alymsys and related rows), and select bevacizumab/biosimilar rows specify non‑cosmetic indication limits. Providers should follow the table annotations when determining allowable indications for these products.

    No supplemental notes are explicitly stated in the provided excerpt. Providers should rely on the step therapy table entries, annotations, and the general coverage conditions (provider‑administered specialty drug, medically accepted indication, and dose/frequency/duration consistent with supporting safety/efficacy) when preparing prior authorization requests.

    Within these fragments there are no standalone clinical exclusions explicitly listed. The content in the provided chunks is primarily mapping of products to step positions and HCPCS/J‑codes; where exclusions apply they are expressed as inline annotations in the step table rather than as a separate exclusion section.

    Certain step entries include targeted exceptions related to pegfilgrastim biosimilars. The table contains wording such as “Does not apply for patients using a pegfilgrastim biosimilar or Rolvedon” (and similar phrasing referencing indications not shared with Fulphila or Neulasta/Neulasta Onpro). When requesting later‑step pegfilgrastim products, providers should confirm whether the specific biosimilar or Rolvedon exceptions apply to the patient’s indication and document accordingly on the authorization.

    Step mappings are presented as code‑driven lists and include occasional caveats. Coverage is tied to the HCPCS/J‑code mapped to each step position, and some rows contain annotations that modify applicability (for example, pegfilgrastim rows noting exceptions). Providers must ensure the selected billing code matches the mapped step position and review inline notes in the table for any special caveats affecting that mapping.

    The provided segments are dominated by code and agent pairings mapped to numbered step positions; they do not include separate clinical exclusion statements. Readers should treat the listed product names and their mapped HCPCS/Q/J codes as the operative pairing for step sequencing and authorization.

    The step tables focus on sequencing and code mappings without explicit clinical exclusion language in these excerpts. Step entries are organized as numbered positions (often followed by “Then one of the following” lists) to indicate allowable agent sequencing; absence of an exclusion statement in these rows does not imply universal coverage outside the listed sequence.

    Several table rows in the extracted text include placeholder or blank numbered positions represented as = . or otherwise empty fields. These blank positions indicate unspecified or intentionally empty step slots in the excerpted portion of the table; providers should not assume additional allowed agents for those blank positions and must follow the explicitly listed agents and codes.

    The policy requires that use for non‑medically accepted indications, or use with dose, frequency, or duration exceeding the safety and efficacy data for the indication, would not meet the general coverage conditions. Requests should document that the dose, frequency, and duration are consistent with supporting evidence for the medically accepted indication and with the policy’s stated coverage conditions.

    Within the provided excerpts there are no explicit statements labeling particular uses or products as not medically necessary. The document does, however, tie coverage to meeting the general coverage conditions (provider‑administered specialty drug, medically accepted indication, and appropriate dose/frequency/duration).

    These chunks do not present explicit not medically necessary (NMN) conditions for individual products. The material focuses on code mappings and step positions; NMN determinations may be specified elsewhere in the full policy outside of these excerpts.

    The supplied text does not include explicit NMN conditions for the products shown. Coverage in these fragments is organized around step sequencing and code mappings; any NMN rules that apply to specific agents are not present in the provided segments.

    Although the document implies that use of agents outside the listed step sequence may be subject to denial, there are no explicit NMN clinical conditions listed in these chunks. Providers should follow the enumerated step sequences and use the specified codes when requesting authorization; non‑sequenced use may require an exception.

    No explicit not medically necessary rules for specific products are present in these fragments. The excerpted step lists and code mappings indicate sequencing expectations; the full policy likely contains detailed NMN criteria in sections not included here.

    Step Therapy Tables and Mappings

    Requested product (step position)Provider must document trial of one of the preferred alternatives prior to coverage
    Alpha-1 Antitrypsin Deficiency, 1 = J0256
    Preferred alternative: Prolastin C (column 2) must be tried and documented
    Step / Requested product (myasthenia gravis group)Mapped HCPCS/CPT/J-code(s) and preferred alternatives (must document trial)
    Generalized Myasthenia Gravis — step 1: Daxxify / Xeomin / Q5152 Q5151 J9256 J9333 J1299
    Step 2: Daxxify / Xeomin with same codes; trial of one listed preferred alternative must be documented
    Step 3: J0588 J0589 J9332 J9334 (toxins/infusion codes) — alternative codes listed for later steps
    Hyaluronic acid derivative (step position)HCPCS / J-code(s) (provider must reference on authorization)
    Durolane — step 1 = J7318
    Gel-One — J7318, J7326 (appears in step mappings)
    GenVisc 850 — J7318 J7326 J7328 J7320
    Euflexxa — J7325 J7323
    Synvisc / Synvisc One — J7322 J7322 (multiple entries) and related codes J7321 etc.
    Step position (1–4)Products / HCPCS-J code groupings (as mapped in policy)
    Step 1 = products mapped to J7318, J7326, J7328, J7320, J7321, J7322
    Step 2 = alternate products mapped to the same J-codes (J7318–J7332) as listed for later steps
    Step 3 = codes shown for third-tier options (e.g., J9332, J9334 referenced for later positions)
    Step 4 = entries often blank or not applicable in this fragment
    Subsequent step positionAlternative products / HCPCS-J codes (document prior step trials)
    Step 2 = listed alternative viscosupplements and other products mapped to J7318–J7332 (examples: Gel-One, GenVisc 850)
    Step 3 = later alternatives or infusion-related codes (J9332, J9334) as shown in mappings
    Step 4 = often shown as '.' (no further alternative) in this fragment
    Step groupProducts included (viscosupplements) and infliximab mapping (codes)
    Viscosupplements group (examples): Monovisc, Orthovisc, Supartz FX, Synvisc, Euflexxa — mapped to J7320–J7332 series
    Infliximab products group: infliximab — mapped to J1745 and Q5121 (Avsola, Remicade, Inflectra, Renflexis appear in listings)
    Documentation must reference the mapped HCPCS/J-code for the product group when requesting authorization
    Step / Product familyRepresentative HCPCS / Q / J codes (partial mapping shown)
    Infliximab family — examples: J1745 (infliximab), Q5121 (Avsola/Remicade biosimilar Q-code), Q5104/Q5103 (Renflexis/Inflectra)
    Pegfilgrastim group — examples: J1449, J9361, Q5130, Q5122, Q5111 (Fylnetra, Nyvepria, Rolvedon, Udenyca listed)
    Note: some pegfilgrastim entries include exception language regarding biosimilars or Rolvedon (see mappings)
    Step positionExample prior agent(s) and codes (pegfilgrastim group — provider must document prior agent)
    Step 1 = Fylnetra Q5130 (or Nyvepria Q5122) — codes to include on PA request
    Step 2 = text notes exceptions: 'Does not apply for patients using a pegfilgrastim biosimilar or Rolvedon for any indication not shared with Fulphila or Neulasta/Neulasta Onpro' — document prior agent as applicable
    Step 3 = additional codes referenced (J1449, J9361) for later-step pegfilgrastim products
    Step position / exampleHCPCS / CPT / J-code and prior agent mapping (pegfilgrastim example included)
    Pegfilgrastim — Fylnetra (Q5130), Nyvepria (Q5122), Rolvedon (J1449) — list corresponding codes on authorization
    Providers must document prior use of listed alternatives (e.g., Neulasta/Neulasta Onpro, Fulphila) where the mapping indicates prior-step requirement
    Therapeutic area / step groupMapped drugs and representative codes (MS, NMOSD, PNH, lysosomal storage examples)
    Multiple Sclerosis / NMOSD — mapped agents: J3385, J0202, J2351, Q5134, Q5120 (examples appear in MS infusions lists)
    Lysosomal storage disorder agents — Cerezyme, Elelyso, VPRIV mapped to codes J2506, J1786, J3060, J2329, J2350 in step lists
    PNH / complement inhibitors — Soliris / Ultomiris mapped to J1299, J1303, Q5151/Q5152 in grouped sequences
    Enumerated step position (initial agent)Then one of the following (allowed alternatives) — product names and codes
    Retinal agents — initial: Avastin / J9035 (Avastin listed with Q/J crosswalks) — Then one of the following: Byooviz, Eylea, Eylea HD, Lucentis (codes Q5124, J9035/C9257, J0178, J0177 shown)
    PNH / complement agents — initial: Uplizna / J1823 and Soliris / J1299 — Then one of the following: related complement/retinal agents as listed
    Step numberAgent/group (initial) and enumerated allowed alternatives (codes)
    Step 1 = Avastin (J0179 / J9035/C9257) — Then one of the following: Byooviz, Eylea, Eylea HD, Lucentis (Q5124, J0178, J0177) as mapped
    Step 2 = subsequent agents listed (Beovu, Cimerli, Enzeevu, Eydenzelt) with Q/J codes Q5149, J2778, Q5153 etc.; providers must document prior trial of step 1 agents
    Step 3–5 = additional listed alternatives (Visudyne, Yesafili and others) with associated codes; some later positions are shown as '.' (no entry)
    Subsequent steps (2–5)Agents and HCPCS/CPT/Q/J codes (providers must document progression)
    Step 2 examples = Beovu / J0179, Cimerli / Q5128, Enzeevu / Q5149, Vabysmo / Q5150; mappings indicate 'Then one of the following' with listed codes
    Step 3 examples = Visudyne (J3396), Yesafili (Q5155) and others — codes must be used on authorization requests
    Steps 4–5 = some entries blank; when listed, include the mapped J/Q codes as shown in the policy

    HCPCS / CPT / Q-Code Mappings

    Alpha-1 antitrypsin product codesHCPCS
    J0256listed for alpha-1 antitrypsin deficiency / Aralast NP
    J0257listed (e.g., Glassia) / alpha-1 antitrypsin products
    Complement inhibitors / Soliris / Ultomiris codesHCPCS
    J1299Soliris (eculizumab) or related entry
    Q5152HCPCS Q-code referenced for complement inhibitors/biosimilars
    Q5151HCPCS Q-code referenced
    Tocilizumab / Actemra codesHCPCS
    J3262Actemra IV (tocilizumab) code
    Q5156tocilizumab-related Q-code
    J3247tocilizumab-anoh IV code
    IL/biologic infusion codesHCPCS
    J2267Cosentyx IV / secukinumab related
    Q9999Q-code referenced for certain ustekinumab/other products
    J0717Omvoh IV related code
    Ustekinumab and related biologicsHCPCS
    J3358ustekinumab / Stelara related J-code
    Q5099Q-code for ustekinumab or related products
    Q5135Q-code referenced for newer biologic products
    J1602infusion code referenced alongside biologics
    Bevacizumab and botulinum toxin codesmixed
    Q5126Alymsys / bevacizumab biosimilar Q-code
    J9035Avastin J-code (bevacizumab)
    Q5160Jobevne Q-code
    Q5129Vegzelma Q-code (botulinum toxin product)
    Botulinum toxins and neuromuscular / MG therapy codesHCPCS
    J0586Botulinum toxin J-code
    J0587Botulinum toxin J-code variant
    J0585Botulinum toxin J-code
    J0589Botulinum toxin J-code
    J9332injectable/infusion code referenced for neuromuscular agents
    J9256epysqli / infusion drug J-code
    J1303Soliris-related J-code
    Myasthenia gravis / specialty drug codesmixed
    Q5152HCPCS code listed in step sequences
    Q5151HCPCS code listed in step sequences
    J9256J-code listed in step sequences
    J9333J-code listed in step sequences
    J1299J-code listed in step sequences
    J1303J-code listed in step sequences
    J1823J-code listed in step sequences
    J9332J-code listed in step sequences
    J9334J-code listed in step sequences
    J0588J-code listed in step sequences
    1–10 of 11
    1/2
    Hyaluronic acid derivative product codesmixed
    J7318Hyaluronic acid derivative code (Durolane, Gel-One, etc.)
    J7326Hyaluronic acid derivative code
    J7328Hyaluronic acid derivative code
    J7320Hyaluronic acid derivative code
    J7321Hyaluronic acid derivative code
    J7322Hyaluronic acid derivative code
    J7323Hyaluronic acid derivative code
    J7325Hyaluronic acid derivative code (Euflexxa)
    J7327Hyaluronic acid derivative code
    HCPCS / J-codes referencedHCPCS
    J1299J1299 (as listed in document)
    J1303J1303 (as listed in document)
    J1823J1823 (as listed in document)
    J7318J7318 (as listed in document)
    J7326J7326 (as listed in document)
    J7328J7328 (as listed in document)
    J7320J7320 (as listed in document)
    J7321J7321 (as listed in document)
    J7322J7322 (as listed in document)
    J7325J7325 (as listed in document)
    1–10 of 16
    1/2
    Viscosupplement HCPCS/J codesHCPCS
    J7320J7320 (as listed)
    J7321J7321 (as listed)
    J7322J7322 (as listed)
    J7323J7323 (as listed)
    J7324J7324 (as listed)
    J7325J7325 (as listed)
    J7326J7326 (as listed)
    J7327J7327 (as listed)
    J7328J7328 (as listed)
    J7329J7329 (as listed)
    1–10 of 12
    1/2
    Infliximab and related HCPCS/Q/J codesHCPCS
    Q5121Q5121 (as listed)
    J1745J1745 infliximab (as listed)
    Q5103Q5103 (as listed)
    Provider-administered specialty product codesmixed
    J1745infliximab
    Q5121infliximab product HCPCS (biosimilars/reference listed)
    Q5104infliximab product HCPCS (Renflexis referenced)
    Q5103infliximab HCPCS (Inflectra referenced)
    J1748infliximab (appears with Zymfentra)
    J7321viscosupplementation/related product code listed in segment
    J7322viscosupplementation/related product code listed in segment
    J7323Euflexxa (viscosupplementation) code reference
    J7324viscosupplementation/related product code listed
    J7327Monovisc or related viscosupplementation code reference
    1–10 of 18
    1/2
    Mapped HCPCS/CPT/J-codes (sample from section)mixed
    Q5130listed in mapping for Fylnetra
    Q5122listed for pegfilgrastim-related mappings
    J1449mapped to several pegfilgrastim/related agents
    Additional mapped codesmixed
    J3385appears in Lysosomal Storage Disorder / MS / NMOSD mappings
    J0202appears in Multiple Sclerosis / NMOSD mappings
    J2351appears in Multiple Sclerosis / NMOSD / PNH mappings
    Q5134appears in MS/infused agent mappings
    Q5120appears in MS/infused agent mappings
    J3060appears in lysosomal storage disorder mappings
    Referenced HCPCS/CPT/Q codesmixed
    J0179listed product code in document
    J1303listed product code in document
    J1307listed product code in document
    J1299listed product code in document
    J1823listed product code in document
    J2778listed product code in document
    J2779listed product code in document
    J2777listed product code in document
    J9035listed product code in document
    C9257listed product code in document
    1–10 of 19
    1/2
    Referenced HCPCS/CPT/Q/J codesmixed
    J0179Injection, ophthalmic anti-VEGF (listed in document)
    J2778Beovu (or listed agent) J-code as referenced
    Q5150Q-code referenced for Vabysmo
    Q5128Q-code referenced for Cimerli or similar
    Q5149Q-code referenced for listed ophthalmic agents
    Q5170Q-code referenced for Yesafili/related
    Q5153Q-code referenced
    Q5147Q-code referenced
    J2779J-code referenced
    J0178J-code referenced
    1–10 of 18
    1/2
    Ophthalmology / selected biologics codesHCPCS
    Q5153Q-code listed with Visudyne/Yesafili group
    Q5147Q-code listed with Visudyne/Yesafili group
    J2779J-code listed with Visudyne/Yesafili group
    J2777J-code listed with Visudyne/Yesafili group
    J3396J-code listed with Visudyne/Yesafili group
    Q5155Q-code listed with Visudyne/Yesafili group
    Q5123Riabni / rituximab products code
    J2778Lucentis-associated J-code
    J0178Avastin-associated J-code
    J0177Avastin-associated J-code
    Additional biologic product codesHCPCS
    J9312Rituxan / rituximab product J-code
    Q5170Lucentis/related Q-code
    Q5149Listed Q-code
    Q5124Byooviz/Eylea group code
    Q5115Truxima code
    Q5119Truxima/Ruxience related code
    Somatostatin & trastuzumab product codesHCPCS
    J1932Somatostatin analogue code
    J2502Signifor LAR code
    J1930Lanreotide/Somatuline related code
    J2353Octreotide/injection code
    J9355Trastuzumab Herceptin J-code
    J9356Herceptin Hylecta J-code
    Q5116Biosimilar code listed
    Q5113Herzuma code
    Q5114Ogivri code
    Q5117Related trastuzumab biosimilar code
    Dose/frequency/duration — Safety and efficacy limit
    Coverage constraintDose, frequency, and duration may not exceed the safety and efficacy data supporting the medically accepted indication.
    ApplicabilityApplies only when the drug is a provider‑administered specialty medication (infused or injected).
    Documentation requirementDocumentation must show therapy is for a medically accepted indication and within supported dosing parameters.
    Step count
    Maximum enumerated stepsStep lists include up to 5 enumerated positions (1 through 5).
    Common step rangeMost product groupings in the document use steps 1–4; some groups list a 5th position when applicable.
    Step interpretationEach numbered step corresponds to an ordered position in the required step‑therapy sequence for that product group.

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization required; include affected HCPCS/CPT/Q/J codes

    Prior authorization is required for medications listed in the step therapy table; requesters must document and request using the applicable HCPCS/CPT/Q/J codes associated with the requested product per the table.

    • See the table rows pairing requested products with specific codes (e.g., J0256, Q5126, J9035, Q5130).
    Prior Authorization

    Request authorization using the correct drug/service code(s)

    Prior authorization is organized around the listed HCPCS/CPT/J‑codes for each drug and step; providers must request authorization using the specific code(s) shown for the product and step.

    • Examples of codes used in step mappings include Q5152, J9256, J1299, J1303.
    Prior Authorization

    Use the mapped HCPCS/J-code for PA tied to step position

    When requesting prior authorization, use the HCPCS/J-code that corresponds to the listed product and its step position in the policy's step therapy mappings.

    • The policy maps products to step positions 1–4 using specific J-codes (e.g., J1299, J1303, J7318, J7326).
    Prior Authorization

    Reference the listed HCPCS/Q/J codes on the authorization

    Authorization requests should reference the listed HCPCS/J‑ and Q‑codes that correspond to the provider‑administered specialty product being requested to demonstrate alignment with the step table.

    • Example codes shown for viscosupplements and infliximab include J7320–J7332 and Q5121/J1745.
    Prior Authorization

    PA tied to specific administration/product codes

    Prior authorization and step‑therapy determinations reference specific HCPCS/CPT/J‑codes for provider‑administered biologics and related products; include those administration/product codes on PA requests.

    • Examples: infliximab group codes (J1745, Q5121, Q5104) and pegfilgrastim codes (J1449, J9361, Q5130).
    Prior Authorization

    PA must include code-to-drug mapping

    Prior authorization must reflect the specific HCPCS/CPT/J‑code(s) mapped to the requested specialty medication per the step therapy table; submit the code that identifies the exact product being requested.

    • Mapped examples across sections include Q5130, Q5122, J1449, J9361 and many product-specific J/Q codes.
    Prior Authorization

    Include the specified product HCPCS/CPT/Q codes on PA

    Prior authorization is organized around the specific HCPCS/CPT/Q‑codes listed for each agent; requests should include the exact code for the administered product as shown in the table.

    • Retinal and PNH product examples reference codes such as J0179, J1303, J1307, Q5150 and others.
    Prior Authorization

    Code‑linked PA: administered drug must match approved code and step

    Prior authorization requires that the administered drug matches an approved HCPCS/CPT/J/Q code and the step sequence in the policy; the PA should demonstrate that the product and code align with the listed step mapping.

    • Ophthalmic groups show Avastin, Byooviz, Eylea and associated J/Q codes mapped to step positions (e.g., J2778, J0179, Q5153).
    Prior Authorization

    PA must use the listed drug HCPCS/CPT/Q/J codes

    Prior authorization is organized around the listed J‑, Q‑ and other HCPCS/CPT codes for each specialty product grouping; providers must request authorization using those listed codes.

    • Examples include J2779, J2777, Q5155, Q5147 and multiple rituximab/trastuzumab codes referenced in step lists.
    Step Therapy

    Step therapy requirement: trial preferred alternative(s) first

    Providers must trial one or more preferred alternative agent(s) listed in the table (column 2) prior to coverage of the requested product, unless otherwise noted in the table.

    • The table states 'Must try one of the following unless otherwise noted' for requested products and lists preferred alternatives by name and code.
    Step Therapy

    Follow numbered step‑therapy sequences by drug and code

    The document lists numbered step‑therapy sequences (1–4, sometimes up to 5) for multiple provider‑administered specialty medications; authorization assessment follows the sequence and associated codes.

    • Myasthenia gravis, viscosupplement, infliximab and other product families are presented with explicit step positions and codes.
    Step Therapy

    Step therapy enforced via HCPCS/J‑code to step mapping

    Step therapy is enforced by mapping specific HCPCS/J‑codes to step positions (1–4); providers must follow the mapped code‑to‑step relationships when requesting later‑step agents.

    • The policy assigns J‑codes such as J7318, J7326, J7328, etc., to step positions across groups.
    Note

    Step product groups enumerated (viscosupplements & infliximab)

    Product groups such as viscosupplements and infliximab products are enumerated as step therapy product groups; providers should reference the group listings and associated codes when planning therapy.

    • Viscosupplement codes include J7320–J7332; infliximab group includes Q5121 and J1745 among others.
    Note

    Step listings present (product step positions shown, details partial)

    Step positions are enumerated for many products (notably infliximab family and viscosupplements); the table shows products placed in positions 1–4 (details partial in this segment).

    • Infliximab entries reference Avsola/Remicade/Inflectra with Q5121/J1745 and step numbers.
    Step Therapy

    Follow drug-to-code step mappings as shown

    Providers must follow the drug‑to‑code step mappings shown: each listed drug or drug group is associated with one or more step positions and specific HCPCS/CPT/J‑codes; use the mapped codes for authorization.

    • Many mapped groups reference prior agents (e.g., Neulasta/Neulasta Onpro, Fulphila) and list corresponding J/Q codes to show sequencing.
    Step Therapy

    Follow enumerated step therapy sequences (initial agent then alternatives)

    Providers must follow the enumerated step therapy pairings where an initial agent is followed by 'Then one of the following' alternatives; the table lists initial agents and allowed alternatives for subsequent steps.

    • Examples include Avastin/Lucentis groups where Avastin is followed by 'Then one of the following' lists (Byooviz, Eylea, Lucentis, etc.).
    Step Therapy

    Adhere to enumerated step sequences; document prior steps

    Providers must follow the step therapy sequencing where an initial agent (often Avastin or another lower‑step drug) is followed by listed alternatives at subsequent steps; authorization of later‑step agents requires documentation of prior steps.

    • Ophthalmic groups list Avastin and then 'one of the following' alternatives with specific J/Q codes for each step position.
    Step Therapy

    Step therapy sequencing follows code‑group based groupings

    Coverage follows step therapy groupings where one listed product/code may be required prior to coverage of another; providers must reference the grouped code listings when requesting coverage.

    • Grouped examples include rituximab/trastuzumab and ophthalmic biologic families with multi‑step code groupings.
    Documentation Required

    Document provider‑administration, indication, and dosing justification

    Documentation must demonstrate the medication is a provider‑administered specialty drug used for a medically accepted indication, and that dose, frequency, and duration align with the safety and efficacy data supporting that indication.

    • The policy preface requires the drug be provider‑administered and used for a medically accepted indication with supported dose/frequency/duration.
    Documentation Required

    Reference specific HCPCS/CPT/J‑code(s) and step number on PA

    Prior authorization requests should reference the specific HCPCS/CPT/J‑code(s) corresponding to the drug and the step number to demonstrate adherence to the step therapy sequence.

    • Include the step number from the table alongside the HCPCS/J‑code(s) listed for the product.
    Documentation Required

    Submit the product‑specific HCPCS/J‑code on the authorization

    Submit the appropriate HCPCS/J‑code that corresponds to the specific product being requested; authorizations should identify the exact product code rather than a generic or alternate code.

    • Hyaluronic acid derivative examples show J7318, J7326, J7328, J7320, etc., assigned to specific products and steps.
    Documentation Required

    Pair product name with the listed HCPCS J/Q codes on submissions

    Use product names paired with their HCPCS J‑ and Q‑codes from the table when completing authorizations and billing to ensure requests match the policy's mappings.

    • Examples in the document pair product names with codes (e.g., J7320–J7332, Q5121, J1745).
    Billing Rule

    Ensure billing/authorization reference the policy's specific product code

    Billing and authorization must reference the specific HCPCS/CPT/J‑code for the administered product as listed in the policy's step tables to support coverage determination.

    • Examples include J1745/Q5121 for infliximab and multiple Q/J codes for pegfilgrastim and ophthalmic agents.
    Billing Rule

    Present drug name/group with corresponding HCPCS/CPT/J code(s)

    Providers must present the drug name/group and corresponding HCPCS/CPT/J‑code(s) that match the step therapy mapping when requesting authorization or submitting claims.

    • The policy repeatedly requires aligning the drug/group name with the listed codes to match step positions.
    Documentation Required

    Document prior agent(s) tried per 'Then one of the following' lists

    Document the chosen agent and, where relevant, the prior agent(s) tried consistent with the 'Then one of the following' step lists to demonstrate that required prior steps were attempted.

    • Ophthalmic and other groups show 'Then one of the following' lists—document prior agents accordingly.
    Billing Rule

    Reference specific HCPCS/CPT/J/Q codes on claims/authorizations

    Claims and authorizations must reference the specific HCPCS/CPT/J/Q codes corresponding to the administered specialty medication as listed in the step sequences.

    • The document lists many specific J/Q codes (e.g., J2778, Q5153, J3396) that should be used on submissions.
    Documentation Required

    Reference the policy's listed HCPCS/J/Q codes when seeking authorization

    Provider authorization requests should reference the exact HCPCS/J‑codes or Q‑codes listed for the specialty product(s) when seeking authorization to ensure alignment with the policy.

    • Ophthalmology and rituximab groups illustrate use of Q5153, Q5147, J2779 and related codes in step lists.
    Denial Risk

    Denial risk if drug is not provider‑administered, indication unsupported, or dosing exceeds evidence

    Requests may be denied if the medication is not a provider‑administered specialty drug, is not being used for a medically accepted indication, or if the requested dose/frequency/duration exceed supported safety and efficacy data.

    • The policy preface lists these three primary coverage conditions as required for coverage.
    Denial Risk

    Denial risk for mismatched HCPCS/CPT/J‑code and step sequence

    Coverage may be determined by whether the requested HCPCS/CPT/J‑codes and the drug sequence align with the step entries listed for the condition; mismatched code or step alignment may lead to denial.

    • Myasthenia gravis and other condition‑specific sequences require code/step alignment (examples show J9256, J9333, J1299 mapped to steps).
    Denial Risk

    Denial risk if code does not match mapped step position/product

    Submissions using HCPCS/CPT/J‑codes that do not match the mapped step position or product may be subject to denial if they do not conform to the policy's step mappings.

    • The policy maps many J‑codes to step positions (e.g., J7318, J7326) and expects submissions to use those mapped codes.
    Denial Risk

    Risk of processing discrepancies if product/code not matched (implicit denial risk)

    The table lists products and codes without explicit denial rules in every chunk, but failure to match products/codes to the authorization request could lead to coding or authorization discrepancies.

    • Where explicit denial language is not repeated, providers should still align requests to the listed mappings to avoid processing issues.
    Denial Risk

    Claims may be subject to step therapy review when using listed HCPCS/CPT/J‑codes

    Claims for listed provider‑administered specialty medications submitted using the listed HCPCS/CPT/J‑codes could be subject to step therapy review or processing aligned with the step listings shown in the policy.

    • Infliximab and viscosupplement groups show code lists that are used to determine step therapy processing.
    Denial Risk

    Nonconforming code or step mapping may trigger denial

    Requests that do not follow the documented step mappings between drug/group and listed HCPCS/CPT/J‑codes may be subject to step therapy requirements and denial if prior steps are not met.

    • The policy indicates prior‑agent requirements for many groups (e.g., pegfilgrastim, MS, NMOSD) and expects adherence to sequencing.
    Denial Risk

    Denial risk for nonconforming step sequence or not using listed substitutes

    Failure to follow the indicated step therapy sequence or to use one of the listed substitute agents (for groups that list 'Then one of the following') may result in denial unless an approved exception is obtained.

    • Several 'Then one of the following' groupings require documentation of prior agents; exceptions are available per the plan's determination process.
    Denial Risk

    Denial risk for use of non‑sequenced agents

    Use of a non‑step agent or failure to follow the listed sequencing of agents as presented (e.g., not following 'Then one of the following' sequences) may trigger denial of coverage.

    • Ophthalmic and biologic groups explicitly list ordered step sequences; do not substitute agents outside those lists without an exception.
    Denial Risk

    Denial risk if step therapy not met — exception process available

    Failure to follow the plan's step therapy requirements may result in denial unless an exception is requested and approved through the organization's determination process.

    • Members may request an exception to the step therapy requirement; such requests are reviewed through the plan's determination process.

    Background

    This policy addresses provider‑administered specialty medications across multiple indications and links coverage to both clinical and coding conditions. Coverage requires that the medication be a provider‑administered specialty drug, be used for a medically accepted indication, and that the dose, frequency, and duration align with supporting safety and efficacy data. The document enforces step therapy sequencing by mapping specific HCPCS/J/Q codes to numbered step positions; prior authorization and claims must reference the mapped code and demonstrate adherence to the step requirements where applicable.

    Definitions

    Provider administered specialty drug
    DefinitionA specialty medication that is administered by a healthcare provider via infusion or injection (provider‑administered).
    Site of careTypically administered in an infusion center, outpatient clinic, or provider office as appropriate for the product.
    Policy roleCoverage and prior authorization requirements in this policy apply only to provider‑administered specialty drugs.
    HCPCS / J‑code (billing code)
    DefinitionHCPCS/J‑code — the billing code used to identify the specific injectable or biologic product for claim and prior authorization submissions.
    Use in policyPrior authorization and step mapping are organized around the HCPCS/J‑code listed for each product and step position.
    Provider actionAuthorization requests must reference the exact HCPCS/J‑code that corresponds to the requested product and step.
    PNH (Paroxysmal Nocturnal Hemoglobinuria)
    AcronymPNH = Paroxysmal Nocturnal Hemoglobinuria.
    Context in policyPNH is referenced in relation to complement/PNH biologics (e.g., Soliris) and their mapped J‑codes (e.g., J1307, J1299).
    ImplicationStep mappings for some complement inhibitors note PNH as an associated indication when listing product/code groupings.
    Step therapy
    DefinitionStep therapy = an ordered coverage approach where treatment must follow a specified sequence (initial preferred agent, then listed alternatives).
    Operational effectProviders must document prior trial(s) of the listed preferred alternative(s) before coverage of a later‑step agent is approved.
    Code linkageStep sequencing is enforced by mapping specific HCPCS/J/Q codes to each numbered step in the policy tables.

    Initial Therapy Criteria

    Initial therapy / step 1

    Initial step requirement

    Try preferred alternatives: For a requested product listed in the table, the provider must document a trial of one of the listed preferred alternative agents (column 2) unless otherwise noted.

    Table rows enumerate the specific preferred alternatives and associated codes that meet the initial step requirement.

    Initial therapy (code-mapped)

    Products are assigned to step positions (1–4) as listed; step 1 products are initial step candidates.

    Initial step mapping: Products identified with '1 =' in the mapping are designated as step 1 (initial) products and are considered first‑line within their step group; subsequent step numbers correspond to later options per the code mapping.

    Chunks list multiple products mapped to numeric step positions; prior authorization must reference the mapped code and step.

    Initial step positions (partial)

    Step positions indicated for listed products (partial data)

    enumeration: The document assigns step numbers to many products (for example, infliximab products and viscosupplements show entries '1 =', '2 =', '3 =', '4 ='); clinical failure rules tied to these positions are not included in this excerpt.

    This is a partial listing of step positions and code mappings.

    Initial step entries

    Many groupings list an initial agent position followed by alternatives.

    Initial agent position: Entries such as '…, 1 = [agent/code]' indicate the initial step agent; those entries are typically followed by 'Then one of the following:' listing allowed alternative agents/codes for subsequent steps.

    Repeated across multiple product groups; up to five enumerated positions may appear.

    Initial therapy (examples)

    Initial step often lists Avastin or a specified first-line agent

    Initial agent: For retinal/ophthalmic agent groupings and other biologic groups, the initial treatment position commonly lists Avastin or another designated first‑step agent; subsequent steps require selecting from the enumerated alternatives.

    Examples in the policy show Avastin and other agents used as initial step entries before permitted alternatives are listed.

    Initial step options (product/code lists)

    Initial step-group listings in this fragment:

    initial_group_examples: For ophthalmic and selected biologic products the document enumerates initial step options and corresponding allowed alternatives (e.g., Byooviz, Eylea, Lucentis, Avastin and rituximab groupings) and maps each to HCPCS/Q/J codes.

    Specific indication‑based initial therapy clinical criteria are not present in these chunks; use the code/step mapping when requesting authorization.

    Site of Care

    Note

    Biosimilar Notes and Mappings

    Note
    Note
    Note
    Note
    Note
    Note